Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D015992:Body Mass Index; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003125:Colostomy; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009656:North America / Q000453:epidemiology; D009765:Obesity / Q000150:complications*; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D012004:Rectal Neoplasms / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D012306:Risk; D012737:Sex Factors; D015996:Survival Rate
D000970:Antineoplastic Agents; D005472:Fluorouracil